Janux Therapeutics Inc. is a biopharmaceutical company focused on the development of novel cancer immunotherapies. The company was founded in 2017 and is headquartered in San Diego, California. Janux Therapeutics leverages its proprietary platform technology, called Tumor Activated T Cell Engager (TRACTM), to create next-generation immunotherapies that target solid tumors.
The TRACTM platform enables the precise activation of T cells, a type of immune cell that plays a critical role in recognizing and eliminating cancer cells. Janux Therapeutics' therapies are designed to selectively engage T cells within the tumor microenvironment, enhancing their ability to specifically target cancer cells while minimizing damage to healthy tissues.
The company's pipeline includes a range of product candidates that are being developed for the treatment of various types of solid tumors. These candidates combine the power of T cell engagement with other therapeutic modalities, such as checkpoint inhibitors, to potentially enhance anti-tumor immune responses and improve patient outcomes.
Janux Therapeutics is dedicated to advancing its pipeline of innovative cancer immunotherapies and bringing potential new treatment options to patients in need. By harnessing the power of the immune system to fight cancer, the company aims to make a meaningful impact in the field of oncology and improve outcomes for patients with solid tumors.